Bashiri Fahad A, Hudairi Abrar, Hamad Muddathir H, Al-Sulimani Lujain K, Al Homyani Doua, Al Saqabi Dimah, Kentab Amal Y, Al Khalifah Reem A
Department of Pediatrics, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.
Division of Pediatric Neurology, Department of Pediatrics, College of Medicine, King Saud University Medical City, King Saud University, Riyadh 11461, Saudi Arabia.
Children (Basel). 2024 Sep 28;11(10):1187. doi: 10.3390/children11101187.
Antiseizure medications (ASMs) are crucial for managing epilepsy in children. However, a well-documented side effect of ASMs is their impact on bone health, often due to interference with vitamin D metabolism. This can lead to vitamin D deficiency in children with epilepsy. This study aimed to determine if a daily dose of 400 IU or 1000 IU would maintain adequate vitamin D levels in children with epilepsy.
A phase IV randomized controlled trial enrolled children aged 2-16 years with epilepsy and receiving antiseizure medications. Children were divided into two groups: the monotherapy group, which was defined as children on one antiseizure medication (ASM), and the polytherapy group, which was defined as children receiving two or more ASMs. Eligible children with levels above 75 nmol/L were randomized to receive a maintenance dose of either 400 IU/day or 1000 IU/day of cholecalciferol. Baseline and 6-month assessments included demographic data, anthropometric measurements, seizure type, medications, seizure control, and 25(OH)D level.
Out of 163 children, 90 were on monotherapy and 25 on polytherapy. After 6 months of vitamin D maintenance, the proportion of children with 25(OH)D concentration below 75 nmol/L was 75.0% in the 400 IU group and 54.8% in the 1000 IU group. In the monotherapy group, baseline seizure-free children increased from 69% to 83.6% after treating vitamin D deficiency.
Daily vitamin D supplementation with 1000 IU may be beneficial for children with epilepsy, particularly those receiving monotherapy, to maintain sufficiency and potentially improve seizure control.
抗癫痫药物(ASMs)对于儿童癫痫的管理至关重要。然而,ASMs一个有充分记录的副作用是它们对骨骼健康的影响,这通常是由于干扰维生素D代谢所致。这可能导致癫痫患儿维生素D缺乏。本研究旨在确定每日400国际单位或1000国际单位的剂量是否能维持癫痫患儿足够的维生素D水平。
一项IV期随机对照试验纳入了年龄在2至16岁、患有癫痫且正在接受抗癫痫药物治疗的儿童。儿童被分为两组:单药治疗组,定义为服用一种抗癫痫药物(ASM)的儿童;多药治疗组,定义为接受两种或更多种ASM的儿童。符合条件且25(OH)D水平高于75 nmol/L的儿童被随机分配接受400国际单位/天或1000国际单位/天胆钙化醇的维持剂量。基线和6个月评估包括人口统计学数据、人体测量、癫痫发作类型、药物、癫痫控制情况以及25(OH)D水平。
163名儿童中,90名接受单药治疗,25名接受多药治疗。维生素D维持治疗6个月后,400国际单位组25(OH)D浓度低于75 nmol/L的儿童比例为75.0%,1000国际单位组为54.8%。在单药治疗组中,治疗维生素D缺乏后,基线时无癫痫发作的儿童从69%增加到83.6%。
每日补充1000国际单位维生素D可能对癫痫患儿有益,尤其是那些接受单药治疗的患儿,有助于维持充足的维生素D水平,并可能改善癫痫控制。